Navigation Links
Beckman Coulter's 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
Date:2/8/2008

n capital expenditures for operating-type leases and the associated depreciation."

Garrett stated, "The continued above-market growth of our clinical diagnostics business was fueled by the introduction of our new UniCel(R) DxI 600 Immunoassay system and a third straight year of record placements of the UniCel(R) DxC 600 and 800 clinical chemistry systems. Demand for our chemistry / immunoassay work cells continues at a rapid pace as demonstrated by a 20% increase in placements for the year. In Clinical Automation, placements accelerated and revenue grew almost 70%."

Full Year 2008 Outlook

The following outlook is based on 2007 adjusted results and does not include special items that may occur in 2008.

"Assuming stable currency, our outlook for full year 2008 revenue growth is 7% to 9%," Garrett continued. "Our goal for the Clinical Diagnostics business is to continue to exceed 10% revenue growth in 2008. We expect revenue from life science products to be about flat with prior year.

"Operating margin for the year should expand to around 12.5%, reflecting our commitment to operating excellence. Non-operating expense is expected to be approximately $11 to $12 million per quarter. Pretax profit growth should be between 13% to 16% and even though we expect a tax rate of 30% to 31%, earnings per diluted share should be $3.50 to $3.65. Capital expenditures are expected to be $290 to $310 million, and depreciation and amortization should be between $240 and $260 million. We expect cash flow to be strong in 2008 as it was in 2007 providing a source for share repurchase."

"In the first quarter, we expect to commercialize our next chemistry / immunoassay work cell, the UniCel(R) DxC 880i, the first of four new work cells coming in 2008. The new UniCel DxH, our next generation hematology system, should be introduced at the end of 2008, and we continue to make solid progress with the development of our DxN 'sample-to-result' instrument f
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
2. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
3. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
4. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
5. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
6. Haemacure Reports Third Quarter 2007 Results
7. Weight Watchers Declares Quarterly Dividend
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. Medical Services International Maintains Pace in Second Quarter
11. Martek Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... STANFORD, Calif. Consider the marvel of the embryo. It ... and function as they multiply to become the cells of ... of the body. , Now, in a feat of reverse ... complex genetic coding that allows embryonic cells to proliferate and ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... the United States have nearly doubled since 1988, suggests new ... with obesity apparently to blame for the surge. The researchers ... hit all groups equally, with alarming increases in diabetes in ... reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... the RECIST Working Group published in the European Journal ... refined categorization of tumor response or various aspects of progression ... They found that modeling target lesion tumor growth did ... that of the other components of progression. The RECIST Working ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, ... certain heart patients will fare about the same whether ... that uses drug-coated stents to prop open clogged arteries. ... procedures, which also require much less recovery time. However, ...
... Cincinnati (UC) and Cincinnati Children,s Hospital Medical Center ... primarily to prevent rejection in organ transplant patients, ... The Multicenter International LAM Efficacy of Sirolimus ... designed to develop a therapy for this life-threatening ...
... MD, MPH, Medical Director and Principal Investigator of IMPACT ... Children,s National Medical Center, served as the Site Principal Investigator ... outcomes, specifically for inner-city children and teens. Findings from a ... were published and released in the March 17 issue of ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... drug cytarabine work as well as the high doses that ... fewer side effects, a new Dutch study finds. Cytarabine ... along with other chemotherapy drugs and stem cell transplantation. Cytarabine ...
... It is no surprise to scientists that the largest social ... their face is fundamental to our social interactions, one of ... how our brain processes facial identity. In a ... scientists used an original approach a method that "shakes" ...
Cached Medicine News:Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 2Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 3Health News:New therapy found for rare lung disorder 2Health News:New therapy found for rare lung disorder 3Health News:Stephen J. Teach, MD, MPH, part of landmark study on pediatric asthma 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Less Is More With Acute Myeloid Leukemia Drug 2Health News:Innovative technique gives vision researchers insight into how people recognize faces 2
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... to the American Cancer Association, prostate cancer affects one ... second leading cause of cancer deaths in men. When ... than 90 percent, making swift treatment key. (See ... however, can be limited and affect quality of life ...
... New Surgery Technique Impacting the Treatment of Women,s Cancers?CHICAGO, ... the fastest growing technological advances in the field of ... surgery (MIS) technique, its impact on the profession, and ... will be some of the topics discussed during the ...
Cached Medicine Technology:VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials 2Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery 2Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery 3
... Control of thumb motion can be ... stroke, for persons with spinal cord injuries ... due to cerebral palsy or other motor ... positions the thumb for control and coordination. ...
... stabilizes the MP joint and the CMC joint of ... of both of the thumb joints. An excellent choice ... but who need maximum mobility for daily activities. Ideal ... thumb and for those with pain due to repetitive ...
... profile contour at the palmar crease to allow ... excellent choice to treat mild to moderate wrist ... wear following cast removal. The lightweight laminated ... fasteners provides support and compression to the wrist ...
... common site for arthritis in the hand. The ... the wrist or other joints of the thumb. ... or reduce subluxation of the CMC joint of ... without pain. Also useful for persons experiencing pain ...
Medicine Products: